新辅助化疗下高危骨肉瘤的临床特点与评价

《新辅助化疗下高危骨肉瘤的临床特点与评价》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、objectiveByanalyzingtheclinicalmanifestations，hematologicalexaminationandX。raychangesof55patientsofosteosarcomabeforeandafterchemotherapy,toanalysistheexpressiondifferencesofthevariousindexunderthenewadjuvantchemotherapyinhighandlow-riskpatients．,todiscussesa

2、ndevaluatetheclinicalcharacteristicofhigh-riskosteosarcoma，andfindtheclinicalindexwhichCandistinguishthehigh-riskosteosarcoma,anddomoreeffectivechemotherapyandsurgeryprogramtoimprovethepatientsqualityoflifeaccordingly．MethodsRetrospectivelyreviewedtheclinical

3、manifestations，hematologicalexaminationandX．raychangesof55patientsofosteosarcomaundertheneoadjuvantchemotherapyintheOrthopeadicDepartmentofJinanMilitaryGeneralHospitalfromDecember，1999toDecember,2006．andFillouttheRegistrationFormforadmission．55casesofosteosar

4、comawerefollowedupfor3to10years，Admissiontothefirsttimestartingupfor3years，Inthe3years，25patientshappenedtorecurrence，metastasisordeath，theseclassifiedashigh·riskgroup，and30patientshadnohappenedtorecurrence，metastasisordeathwhichclassifiedaslow-riskgroup．Stat

5、thesex，agelocation，duration,limbpain，changesbeforeandafterchemotherapy,changesinvaricoseveinsbeforeandafterchemotherapy,tumorsize，XraytypetheX-score，beforeandafterchemotherapy，theAKPandLDHlevelandotherindicators．Analyzeandsummarizethecharacteristicsoftheseind

6、icatorsandthechangesbeforeandafterchemotherapy,andusethestatisticalmethods(chi—square，ttestandnon。condi-tionalLogisticregressionanalysis)totoanalysistheexpressiondifferencesofthevariousindexunderthenewadjuvantchemotherapyinhighandlow-riskpatients，todiscussesa

7、ndevaluatetheclinicalcharacteristicofhigh—riskosteosarcoma,andfindtheclinicalindexwhichCandistinguishthehigh—riskosteosarcoma．5Results：1．Thebasicresults：55easesoccurredinpatientswithmetastasis，recurrenceordeathin25eases，45％；normalsurvivalin30cases，accountingf

8、or55％．Bloodtestsbeforeandafterchemotherapy,nosignificantchangeandincreaseof9patients，7easesofhigh—riskgroup，accountingfor77％，low-riskgroup，2patients，only23％．Clinicalevaluationofchemothera